Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3802196 | 0.88 | HSD11B1 (0.39) | MDM2MCL1HSD11B1MCHR1GAA | |
| SCHEMBL3665796 | 0.87 | HSD11B1 (0.37) | HSD11B1MEN1KMT2AMCHR1NPC1 | |
| SCHEMBL3667493 | 0.85 | HSD11B1 (0.38) | HSD11B1MCHR1 | |
| SCHEMBL9982786 | 0.84 | LIPE (0.39) | HSD11B1MCHR1SCN9A | |
| SCHEMBL3721757 | 0.82 | HSD11B1 (0.38) | HSD11B1MCHR1NPC1GAAHTT | |
| SCHEMBL3664852 | 0.79 | HSD11B1 (0.41) | HSD11B1TP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL975542 | 0.79 | HSD11B1 (0.62) | HSD11B1 | |
| SCHEMBL3662832 | 0.78 | HRH3 (0.43) | HSD11B1MCHR1 | |
| SCHEMBL27809384 | 0.76 | SLC6A7 (0.43) | HSD11B1SCN9A | |
| SCHEMBL3791025 | 0.76 | HRH3 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238126-B1 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | claimed |
| US-8211892-B2 | Tetrahydroquinoxaline urea derivatives | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | claimed |
| CN-101981026-A | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic use | SANOFI AVENTIS | 2011-02-23 | — | — | CN | claimed |
| EP-2238126-A2 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | claimed |
| WO-2009112691-A2 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | claimed |
| EP-2238126-B1 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | disclosed |
| US-8530657-B2 | Substituted adamantanes and their therapeutic application | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| US-20120245148-A1 | TETRAHYDROQUINOXALINE UERA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-8211892-B2 | Tetrahydroquinoxaline urea derivatives | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | disclosed |
| CN-101981026-A | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic use | SANOFI AVENTIS | 2011-02-23 | — | — | CN | disclosed |
| EP-2238126-A2 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009112691-A2 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245148-A1 | TETRAHYDROQUINOXALINE UERA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | UGDH, HNMT, NNMT | MDM2 560/4885MCL1 2583/4885HSD11B1 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.